To assess the involvement of metalloproteinases and particularly ADAM10 in Fat1 ectodomain shedding, human pancreatic cancer cells were treated with the broad spectrum protease inhibitor Batimastat and the ADAM10 specific inhibitor GI245023X [28], [29]. This evidence concerns the gene FAT1 and pancreatic neoplasm.